Scholarlink

<p>In recent years, multiple molecularly defined entities have emerged in head and neck pathology, especially among sinonasal squamous and basaloid carcinomas, including NUT carcinoma, SWI/SNF-deficient carcinoma, and <i>DEK</i>::<i>AFF2</i> carcinoma. These tumors show significant morphological and immunophenotypic diversity. We present five novel head and neck carcinomas harboring <i>AFF2</i> rearrangements involving previously unreported fusion partners. Five cases (3 males, 2 females; ages 35–72&#xa0;years) presented with tumors in the sinonasal region (<i>n</i> = 4) and parotid gland (<i>n</i> = 1), measuring between 3.3 and 6.3&#xa0;cm. RNA sequencing identified fusions involving <i>AFF2</i> with <i>H3-3A</i>, <i>EWSR1</i>, <i>CHD4</i> (two cases: neck lymph node metastasis, which turned out to be sinonasal primary and parotid mass), and <i>NUCKS1</i>. Tumors harboring <i>H3-3A</i>::<i>AFF2</i> and <i>NUCKS1</i>::<i>AFF2</i> fusions exhibited bland transitional cell-like morphology with acantholytic changes similar to classic <i>DEK</i>::<i>AFF2</i> carcinoma; the <i>NUCKS1</i> fusion also demonstrated clear cell features. In contrast, the <i>EWSR1</i>::<i>AFF2</i> fusion tumor showed high-grade adenocarcinoma morphology with focal neuroendocrine marker expression, lacking p63 and CK5/6. The two <i>CHD4</i>::<i>AFF2</i> fusion cases demonstrated neuroendocrine differentiation; one was a cytokeratin-negative small blue round cell carcinoma, and the other showed mixed squamoid-neuroendocrine features with strong cytokeratin and p63 expression. All tumors demonstrated consistent AFF2 immunoreactivity. These findings suggest that <i>AFF2</i>-rearranged tumors form a spectrum of carcinomas with diverse morphologies, immunophenotypes, and differentiation patterns. Given the consistent involvement of the <i>AFF2</i> gene and uniform AFF2 immunohistochemical positivity despite morphological heterogeneity, we propose naming this entity AFF2 carcinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Expanding the spectrum of AFF2 carcinoma: clinical, morphological, immunohistochemical, and molecular characteristics of five cases harboring alternate fusions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月10日

查看全文
  • Gerben E. Breimer,
  • Martin D. Hyrcza,
  • Elan Hahn,
  • Sophie C. Prendergast,
  • Stephen M. Smith,
  • Anne Chambers,
  • Emma Todorovic,
  • Doreen Palsgrove,
  • Daniel L. Miller,
  • Robert J. Heinhuis,
  • Johannes A. Rijken,
  • Lennart A. Kester,
  • Cuihong Wei,
  • Ilan Weinreb,
  • Justin A. Bishop

摘要

In recent years, multiple molecularly defined entities have emerged in head and neck pathology, especially among sinonasal squamous and basaloid carcinomas, including NUT carcinoma, SWI/SNF-deficient carcinoma, and DEK::AFF2 carcinoma. These tumors show significant morphological and immunophenotypic diversity. We present five novel head and neck carcinomas harboring AFF2 rearrangements involving previously unreported fusion partners. Five cases (3 males, 2 females; ages 35–72 years) presented with tumors in the sinonasal region (n = 4) and parotid gland (n = 1), measuring between 3.3 and 6.3 cm. RNA sequencing identified fusions involving AFF2 with H3-3A, EWSR1, CHD4 (two cases: neck lymph node metastasis, which turned out to be sinonasal primary and parotid mass), and NUCKS1. Tumors harboring H3-3A::AFF2 and NUCKS1::AFF2 fusions exhibited bland transitional cell-like morphology with acantholytic changes similar to classic DEK::AFF2 carcinoma; the NUCKS1 fusion also demonstrated clear cell features. In contrast, the EWSR1::AFF2 fusion tumor showed high-grade adenocarcinoma morphology with focal neuroendocrine marker expression, lacking p63 and CK5/6. The two CHD4::AFF2 fusion cases demonstrated neuroendocrine differentiation; one was a cytokeratin-negative small blue round cell carcinoma, and the other showed mixed squamoid-neuroendocrine features with strong cytokeratin and p63 expression. All tumors demonstrated consistent AFF2 immunoreactivity. These findings suggest that AFF2-rearranged tumors form a spectrum of carcinomas with diverse morphologies, immunophenotypes, and differentiation patterns. Given the consistent involvement of the AFF2 gene and uniform AFF2 immunohistochemical positivity despite morphological heterogeneity, we propose naming this entity AFF2 carcinoma.